^
    Back
    Association details:
    Biomarker:TMB-H + PD-L1 underexpression
    Cancer:Pancreatic Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review

    Published date:
    08/27/2021
    Excerpt:
    Here, we reported a Chinese patient with pancreatic cancer, a high TMB and low expression of PD-L1 who responded well to the combined therapy of pembrolizumab and chemotherapy.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1097/CAD.0000000000001232